小RNA
彪马
癌症
细胞凋亡
转染
信使核糖核酸
癌细胞
癌症研究
单克隆抗体
肝细胞癌
细胞内
免疫系统
生物
细胞生物学
抗体
细胞培养
免疫学
基因
生物化学
遗传学
作者
Ruchi Jain,Josh P. Frederick,Eric Yi‐Hsiu Huang,Kristine Burke,David Mauger,Elizaveta A. Andrianova,Sam Farlow,Summar Siddiqui,Jeffrey Pimentel,Kahlin Cheung-Ong,Kristine McKinney,Caroline Köhrer,Melissa J. Moore,Tirtha Chakraborty
出处
期刊:Nucleic Acid Therapeutics
[Mary Ann Liebert, Inc.]
日期:2018-08-08
卷期号:28 (5): 285-296
被引量:160
标识
DOI:10.1089/nat.2018.0734
摘要
The advent of therapeutic mRNAs significantly increases the possibilities of protein-based biologics beyond those that can be synthesized by recombinant technologies (eg, monoclonal antibodies, extracellular enzymes, and cytokines). In addition to their application in the areas of vaccine development, immune-oncology, and protein replacement therapies, one exciting possibility is to use therapeutic mRNAs to program undesired, diseased cells to synthesize a toxic intracellular protein, causing cells to self-destruct. For this approach to work, however, methods are needed to limit toxic protein expression to the intended cell type. Here, we show that inclusion of microRNA target sites in therapeutic mRNAs encoding apoptotic proteins, Caspase or PUMA, can prevent their expression in healthy hepatocytes while triggering apoptosis in hepatocellular carcinoma cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI